The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to proposals made by the National Institute for Health and Care Excellence (Nice). Previously, it was only available on the NHS for patients with diabetes.
Under Nice’s proposals, the drug will gradually be rolled out over the next three years. Access to it will first be prioritised to patients who are severely obese and have at least three weight-related health problems – for example, cardiovascular disease, hypertension, high cholesterol and sleep apnoea.
